Moderna Evaluates Smaller Doses of COVID-19 Vaccine for Teens and Children

As Moderna waits for the FDA’s decision on emergency use authorization (EUA) of its COVID-19 vaccine for 12-17-year-olds at 100-microgram standard doses, the drugmaker is testing the efficacy and safety of smaller doses. Moderna’s EUA application came weeks before warnings about myocarditis were added to the fact sheet of the vaccine, which had a higher risk of the condition than Pfizer’s RNA vaccine.

According to Lauren Gardner and David Lim in Politico’s Prescription Pulse, “Moderna executives said the company is now testing 50-microgram doses for the adolescent series and 25 micrograms for the pediatric series, nodding to FDA’s influence. It expects data on children 6 months to 5 years old by the end of the first quarter.”

Read more by clicking here.

(Source: Politico, February 25^th, 2022)